Fennec Pharmaceuticals Inc (FENC)

$8.43 +0.53 (6.71%)
Market Cap 211.98M
Revenue (ttm) 47.54M
Net Income (ttm) -440,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 214.77
Profit Margin -0.93%
Debt to Equity Ratio -3.07
Volume 120,900
Avg Vol 86,792
Day's Range N/A - N/A
Shares Out 27.62M
Stochastic %K 44%
Beta 0.40
Analysts Strong Sell
Price Target $12.80

Latest News on FENC

Fennec Announces Results of Annual Meeting

Jun 3, 2025, 4:31 PM EDT - 3 days ago

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript

May 13, 2025, 12:23 PM EDT - 24 days ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

May 8, 2025, 4:17 PM EDT - 4 weeks ago

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript

Mar 10, 2025, 10:24 AM EDT - 3 months ago

Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 6:03 AM EDT - 3 months ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Mar 6, 2025, 4:22 PM EST - 3 months ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Feb 7, 2025, 7:00 AM EST - 4 months ago

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Dec 20, 2024, 6:16 AM EST - 6 months ago

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Dec 19, 2024, 6:13 AM EST - 6 months ago

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Dec 12, 2024, 7:01 AM EST - 6 months ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

Nov 9, 2024, 10:33 PM EST - 7 months ago

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 6:13 AM EST - 7 months ago

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 31, 2024, 6:23 AM EDT - 7 months ago

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Oct 28, 2024, 6:23 AM EDT - 7 months ago

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 5, 2024, 6:56 AM EDT - 9 months ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 2:20 PM EDT - 10 months ago

Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 6:05 AM EDT - 10 months ago

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Aug 6, 2024, 4:31 PM EDT - 10 months ago

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Aug 5, 2024, 6:26 AM EDT - 10 months ago

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Fennec Pharmaceuticals Announces Management Change

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Fennec Pharmaceuticals Announces Management Change

Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript

May 14, 2024, 1:15 PM EDT - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 6:03 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

May 7, 2024, 6:15 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 12:30 PM EDT - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q4 2023 Earnings Call Transcript

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Mar 21, 2024, 6:00 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Mar 19, 2024, 6:01 AM EDT - 1 year ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Mar 17, 2024, 9:00 PM EDT - 1 year ago

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price

Mar 6, 2024, 8:39 PM EST - 1 year ago

Fennec Pharmaceuticals: Great Sales Progress - Not Yet Reflected In Stock Price

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Feb 29, 2024, 7:04 AM EST - 1 year ago

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Feb 1, 2024, 5:55 AM EST - 1 year ago

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Fennec Announces Incremental $5 Million Investment from Petrichor

Dec 5, 2023, 5:55 AM EST - 1 year ago

Fennec Announces Incremental $5 Million Investment from Petrichor

Fennec Pharmaceuticals Expands Possible TAM Significantly

Nov 9, 2023, 6:24 PM EST - 1 year ago

Fennec Pharmaceuticals Expands Possible TAM Significantly

Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 11:19 AM EST - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q3 2023 Earnings Call Transcript

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:59 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 30, 2023, 6:45 AM EDT - 1 year ago

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript

Aug 6, 2023, 9:00 AM EDT - 1 year ago

Fennec Pharmaceuticals Inc. (FENC) Q2 2023 Earnings Call Transcript

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Aug 3, 2023, 5:59 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Jul 31, 2023, 5:30 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Jun 6, 2023, 5:44 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript

May 13, 2023, 11:34 PM EDT - 2 years ago

Fennec Pharmaceuticals Inc. (FENC) Q1 2023 Earnings Call Transcript

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 6:01 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

May 8, 2023, 6:15 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

Fennec Pharmaceuticals: Undervalued, Near-Cash-Flow-Positive, Possible Buyout Candidate

Apr 26, 2023, 8:33 AM EDT - 2 years ago

Fennec Pharmaceuticals: Undervalued, Near-Cash-Flow-Positive, Possible Buyout Candidate

Fennec Pharmaceuticals Gains Momentum With Industry Endorsements

Apr 5, 2023, 8:43 AM EDT - 2 years ago

Fennec Pharmaceuticals Gains Momentum With Industry Endorsements

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Mar 31, 2023, 8:03 AM EDT - 2 years ago

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Mar 30, 2023, 5:55 AM EDT - 2 years ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

Jan 31, 2023, 6:00 AM EST - 2 years ago

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

Jan 25, 2023, 7:19 AM EST - 2 years ago

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale

Jan 16, 2023, 5:45 AM EST - 2 years ago

Fennec Pharmaceuticals: Ruminating The Prospects And Necessity Of A Sale

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

Nov 11, 2022, 7:10 AM EST - 2 years ago

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update